{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:59:56Z","timestamp":1772819996539,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ygyno.2019.10.014","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T17:26:19Z","timestamp":1585761979000},"page":"585-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma"],"prefix":"10.1016","volume":"157","author":[{"given":"L.R.","family":"Duska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Varhegyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jelovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.P.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.M.","family":"Barroilhet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2019.10.014_bib1","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Canc. J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.014_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Canc."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.014_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2019.10.014_bib4","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.014_bib5","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0090-8258(03)00011-8","article-title":"Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer","volume":"88","author":"D\u2019Agostino","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.014_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"2 Pt 2","key":"10.1016\/j.ygyno.2019.10.014_bib7","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0090-8258(03)00340-8","article-title":"Gemcitabine as a single-agent treatment for ovarian cancer","volume":"90","author":"Fowler","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.014_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1040-8428(03)00119-7","article-title":"Gemcitabine: current role and future options in the treatment of ovarian cancer","volume":"48","author":"Fruscella","year":"2003","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.014_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.ygyno.2019.10.014_bib10","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0305-7372(05)80006-4","article-title":"Gemcitabine in patients with ovarian cancer","volume":"31","author":"Poveda","year":"2005","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.014_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/02841860500509035","article-title":"Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients","volume":"45","author":"Safra","year":"2006","journal-title":"Acta Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.ygyno.2019.10.014_bib12","doi-asserted-by":"crossref","first-page":"v188","DOI":"10.1093\/annonc\/mdj979","article-title":"Role of gemcitabine in ovarian cancer treatment","volume":"17","author":"Lorusso","year":"2006","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.014_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/ijgc-00009577-200511000-00002","article-title":"Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives","volume":"15","author":"Lorusso","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2019.10.014_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1023\/A:1008469212268","article-title":"A\u00a0phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer","volume":"9","author":"Friedlander","year":"1998","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2019.10.014_bib15","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.10.014_bib16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00280-018-3552-5","article-title":"Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis","volume":"81","author":"Takasaki","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"no 15_supple17064","key":"10.1016\/j.ygyno.2019.10.014_bib17","article-title":"Feasibility of bevacizumab combined with gemictabine in treatment of platinum-resistant epithelial ovarian cancer","volume":"35","author":"Kogiku","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.014_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A\u00a0Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"30","key":"10.1016\/j.ygyno.2019.10.014_bib19","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"no, 15_suppl","key":"10.1016\/j.ygyno.2019.10.014_bib20","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1200\/JCO.2018.36.15_suppl.5518","volume":"36","author":"Vergote","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.014_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"issue":"14","key":"10.1016\/j.ygyno.2019.10.014_bib22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/sim.1193","article-title":"Designing complex group sequential survival trials","volume":"21","author":"Lakatos","year":"2002","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.014_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: a randomized clinical trial","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2019.10.014_bib24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819315975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:09Z","timestamp":1758772329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819315975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0090825819315975"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.014","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}